Public research and industrial innovation: A comparison of US and European innovation systems in the life sciences

Science and Innovation: Rethinking the Rationales for Funding and Governance

Volumn , Issue , 2003, Pages 169-193

  Riccaboni, Massimo ^a   Powell, Walter W ^b   Pammolli, Fabio ^c   Owen Smith, Jason ^d  

^a UNIVERSITY OF SIENA   (Italy)

^b STANFORD UNIVERSITY   (United States)

^c UNIVERSITY OF FLORENCE   (Italy)

^d UNIVERSITY OF MICHIGAN   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 22644434340     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.4337/9781781950241.00019     Document Type: Chapter

References (35)

1. Albert, R., H. Jeong, and A. Barabasi (2000), 'Error and attack tolerance in complex networks', Nature 406(July), 378-82.
2. Arora, A. and A. Gambardella (1990), 'Complementarity and external linkages: the strategies of large firms in biotechnology', Journal of Industrial Economics, 38(4), 361-79.
3. Arora, A. and A. Gambardella (1994), 'Explaining technological information and utilizing it: scientific knowledge, capacity, and external linkages in biotechnology', Journal of Economic Behavior and Organization, 24, 91-114.
4. Arora, A., A. Gambardella, F. Pammolli and M. Riccaboni (2000), 'The nature and the extent of the market for technology in biopharmaceuticals', Paper presented at the 'International Conference on Technology Policy and Innovation:Economic and Historical Perspectives', Paris, 20-22 November.
5. Batagelj, V. and A. Mrvar (2000), 'Drawing genealogies', Connections, 21, 47-57.
6. Ben-David, J. (1977), Centers of Learning: Britain, France, Germany, and the United States, New York: McGraw-Hill.
7. Fruchterman, T. and E. Reingold (1991), 'Graph drawing by force-directed replacement', Software - Practice and Experience, 21, 1129-64.
8. Galambos, L. and J. Sturchio (1998), 'Pharmaceutical firms and the transition to biotechnology: a study in strategic innovation, Business History Review 72, 250-78.
9. Gambardella, A. (1995), Science and Innovation. The U.S. Pharmaceutical Industry During the 1980s, New York: Cambridge University Press.
10. Gambardella, A., L. Orsenigo and F. Pammolli (2000), 'Global competitiveness in pharmaceuticals: a European perspective', Enterprise Papers, No. 1 (http://dg 3.eudra.org/pharmacos/comdoc_doc.htm).
11. Geiger, R. (1988), Research and Relevant Knowledge: American Research Universities since World War II, New York: Oxford University Press.
12. Gittelman, M. (2000), 'Mapping national knowledge networks: scientists, firms and institutions in biotechnology in the United States and France', PhD Dissertation, New York University.
13. Guyon, X. (1994), Random Fields on a Network, Berlin: Springer.
14. Henderson, R., L. Orsenigo and G. Pisano (1999), 'The pharmaceutical industry and the revolution in molecular biology', in Mowery and Nelson (eds), pp. 267-311.
15. Howells, J. and C. McKinlay (1999), 'Commercialization of university research in Europe. Report to the Advisory Council on Science and Technology', Ontario, Canada.
16. Ising, E. (1925), 'Beitrag zur theorie des ferromagnetismus', Zeitschrift Physik, 31, 235-58.
17. Lerner, J. and R. Merges (1998), 'The control of technology alliances: an empirical analysis of the biotechnology industry', Journal of Industrial Economics, 46(2), 125-56.
18. Liebeskind, J., A. Oliver, L. Zucker and M. Brewer (1996), 'Social networks, learning, and flexibility: sourcing scientific knowledge in new biotechnology firms', Organizational Science, 7(4), 428-43.
19. Link, A. (1999), 'Public/private partnerships in the United States', Industry and Innovation, 6(2), 191-217.
20. Morange, M. (1998), A History of Molecular Biology, Cambridge, MA: Harvard University Press.
21. Mowery,D. (1999), 'America's industrial resurgence? An overview', in U.S. Industry in 2000: Studies in Competitive Performance, Washington, DC: National Academy Press, pp. 1-16.
22. Mowery, D. and R.R. Nelson (eds) (1999), Sources of Industrial Leadership. Studies of Seven Industries, New York: Cambridge University Press.
23. Mowery, D., R.R. Nelson, B.N. Sampat and A.A. Ziedonis (2001), 'The growth of patenting and licensing by U.S. universities: an assessment of the effects of the Bayh-Dole Act of 1980', Research Policy, 30(1), 99-119.
24. Orsenigo, L., F. Pammolli and M. Riccaboni (2001), 'Technological change and network dynamics. Lessons from the pharmaceutical industry', Research Policy, 30(3), 485-508.
25. Owen-Smith, J. (2000), 'Public science, private science: the causes and consequences of patenting by Research One universities', PhD Dissertation, University of Arizona.
26. Owen-Smith, J.,M. Riccaboni, F. Pammolli and W.W. Powell (2002) 'A comparison of US and European university-industry relations in the life sciences', Management Science 48(1), 24-43.
27. Pammolli, F., M. Riccaboni and L. Orsenigo (2000), 'Variety and irreversibility in scientific and technological systems', in A. Nicita and U. Pagano (eds), The Evolution of Economic Diversity, London: Routledge, pp. 216-39.
28. Pavitt, K. (2000) 'Academic research in Europe', SPRU Working Paper, no. 43, Science and Technology Policy Research, Brighton.
29. Peterson, J. and M. Sharp (1998), Technology Policy in the European Union, Basingstoke: Macmillan.
30. Powell,W.W., K.W. Koput and L. Smith-Doerr (1996), 'Interorganizational collaboration and the locus of innovation in biotechnology', Administrative Science Quarterly, 41(1), 116-45.
31. Rosenberg, N. and R.R. Nelson (1994), 'American universities and technical advance in industry', Research Policy, 23(3), 323-48.
32. Stokes, D.E. (1997), Pasteur's Quadrant, Washington, DC: Brookings Institution Press.
33. Stuart, T.E., H. Hoang and R.C. Hybels (1999), 'Interorganizational endorsements and the performance of entrepreneurial ventures', Administrative Science Quarterly, 44, 315-49.
34. Winkler, G. (1995), 'Image analysis, random fields and dynamic Monte Carlo models', Applications of Mathematics 27, Berlin: Springer Verlag.
35. Zucker, L.G., M.R. Darby and M.B. Brewer (1997), 'Intellectual human capital and the birth of U.S. biotechnology enterprises', American Economic Review, 88(1), 290-306.